Search Results

86 articles with title/keywords/abstract containing Decision-Resources

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
modify search
Display per page 

Sales of human epidermal growth factor receptor 2 (HER2)-targeting breast cancer therapies are set to grow by 3.3% per annum

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 592, 2009-11-28 , pp. 11-11(1)

Publisher: Adis International

Patient flow to Humira [adalimumab] and Enbrel [etanercept] will be negatively affected by the introduction of Stelara [ustekinumab]

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 592, 2009-11-28 , pp. 11-11(1)

Publisher: Adis International

Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Gastric cancer drug market to grow through targeted therapies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Decision Resources predicts that the bipolar disorder drug market will decline by more than $US1 billion over the next decade.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Nearly one-fifth of eligible cancer patients in the US fail to receive Avastin [bevacizumab] due to its high cost

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 8-8(1)

Publisher: Adis International

The breast cancer drug market in China is expected to grow from $165 million in 2008 to $298 million in 2013

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 11-11(1)

Publisher: Adis International

According to a new report by Decision Resources, the launch of targeted agents and the increased use of existing agents

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 582, 2009-07-11 , pp. 11-11(1)

Publisher: Adis International

Europe pays less for drugs than the US

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 582, 2009-07-11 , pp. 11-11(1)

Publisher: Adis International

A recent report has predicted that hepatitis C virus (HCV) drug sales will almost quadruple by 2013, across major markets.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 581, 2009-06-27 , pp. 10-10(1)

Publisher: Adis International

The growth of drug sales of the top ten pharmaceutical companies slowed in 2008

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 579, 2009-05-30 , pp. 15-15(1)

Publisher: Adis International

The small cell lung cancer (SCLC) drug market is predicted to double by 2017, despite "disappointing" drug development in this area

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 576, 2009-04-18 , pp. 15-15(1)

Publisher: Adis International

New products will drive growth of almost $US5 billion in the coronary heart disease (CHD) market, despite patent expirations affecting leading therapies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 575, 2009-04-04 , pp. 10-10(1)

Publisher: Adis International

Specialists alter TNF-α inhibitor prescribing due to investigation

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 575, 2009-04-04 , pp. 10-10(1)

Publisher: Adis International

Specialists alter TNF-α inhibitor prescribing due to investigation

Source: Reactions, Volume 1, Number 1246, 2009-04-04 , pp. 4-4(1)

Publisher: Adis International

As a result of the JUPITER trial, 65% of surveyed managed care organisation (MCO) pharmacy directors

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 573, 2009-03-07 , pp. 10-10(1)

Publisher: Adis International

According to a report by Decision Resources, 70.7% of patients who are newly diagnosed with Alzheimer's disease

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 573, 2009-03-07 , pp. 10-10(1)

Publisher: Adis International

Increasing use of ranibizumab [Lucentis; Genentech, Novartis Opthalmics] will drive robust growth in the AMD market

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 574, 2009-03-21 , pp. 11-11(1)

Publisher: Adis International

The use of bevacizumab [Avastin] and cetuximab [Erbitux] will drive the colorectal cancer market to grow by almost $1 billion in 2017

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 574, 2009-03-21 , pp. 11-11(1)

Publisher: Adis International

Payers look to intensify cost-containment measures

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 572, 2009-02-21 , pp. 10-10(1)

Publisher: Adis International

modify search
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A